Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
2.060
-0.090 (-4.19%)
Aug 28, 2026, 2:41 PM EDT - Market open
Acrivon Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 41.42 | 41.5 | 39.82 | 36.02 | 29.52 | 99.6 |
Short-Term Investments | 48.54 | 77.08 | 139.66 | 91.44 | 98.23 | - |
Cash & Short-Term Investments | 89.96 | 118.58 | 179.48 | 127.46 | 127.75 | 99.6 |
Cash Growth | -34.54% | -33.93% | 40.81% | -0.23% | 28.26% | 6192.04% |
Prepaid Expenses | 1.53 | 1.86 | 2.15 | 2.23 | 4.34 | 0.81 |
Total Current Assets | 91.49 | 120.45 | 181.63 | 129.69 | 132.1 | 100.41 |
Property, Plant & Equipment | 6.23 | 7.42 | 8.03 | 7.91 | 6.86 | 5.79 |
Long-Term Investments | - | - | 5.09 | - | 41.88 | - |
Long-Term Deferred Charges | - | 0.5 | - | - | - | - |
Other Long-Term Assets | 1.37 | 1.36 | 1.85 | 0.67 | 0.39 | 0.39 |
Total Assets | 99.09 | 129.72 | 196.59 | 138.27 | 181.23 | 106.59 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.86 | 2.28 | 0.76 | 5.05 | 0.9 | 0.96 |
Accrued Expenses | 9.45 | 12.07 | 15.4 | 7.38 | 4.14 | 1.22 |
Current Portion of Leases | 1.14 | 1.17 | 1.06 | 0.88 | 0.73 | 0.66 |
Current Unearned Revenue | - | - | - | - | 0.07 | 0.07 |
Other Current Liabilities | - | 0.14 | - | - | 0.67 | - |
Total Current Liabilities | 11.45 | 15.66 | 17.21 | 13.3 | 6.52 | 2.91 |
Long-Term Leases | 0.98 | 1.54 | 2.59 | 3.77 | 4.24 | 4.96 |
Total Liabilities | 12.43 | 17.2 | 19.8 | 17.07 | 10.75 | 7.88 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0 |
Additional Paid-In Capital | 398.54 | 387.26 | 373.28 | 237.68 | 226.58 | 1.05 |
Retained Earnings | -311.89 | -274.88 | -196.98 | -116.42 | -56.03 | -24.87 |
Comprehensive Income & Other | -0.03 | 0.11 | 0.45 | -0.08 | -0.1 | - |
Total Common Equity | 86.67 | 112.52 | 176.79 | 121.2 | 170.48 | -23.81 |
Shareholders' Equity | 86.67 | 112.52 | 176.79 | 121.2 | 170.48 | 98.71 |
Total Liabilities & Equity | 99.09 | 129.72 | 196.59 | 138.27 | 181.23 | 106.59 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.12 | 2.71 | 3.65 | 4.64 | 4.96 | 5.63 |
Net Cash (Debt) | 87.84 | 115.87 | 175.84 | 122.81 | 122.79 | 93.98 |
Net Cash Growth | -34.52% | -34.10% | 43.17% | 0.02% | 30.66% | 6062.30% |
Net Cash Per Share | 2.23 | 3.01 | 5.20 | 5.56 | 29.79 | 53.90 |
Filing Date Shares Outstanding | 42.85 | 38.74 | 31.35 | 22.64 | 21.92 | 1.77 |
Total Common Shares Outstanding | 42.85 | 31.65 | 31.23 | 22.52 | 21.92 | 1.77 |
Working Capital | 80.05 | 104.78 | 164.42 | 116.39 | 125.58 | 97.49 |
Book Value Per Share | 2.02 | 3.56 | 5.66 | 5.38 | 7.78 | -13.45 |
Tangible Book Value | 86.67 | 112.52 | 176.79 | 121.2 | 170.48 | -23.81 |
Tangible Book Value Per Share | 2.02 | 3.56 | 5.66 | 5.38 | 7.78 | -13.45 |
Machinery | 8.35 | 7.29 | 6.38 | 3.13 | 2.51 | 0.35 |
Construction In Progress | - | 0.92 | 0.06 | 1.31 | - | - |